1
|
Liang C, Zhou Y, Xin L, Kang K, Tian L, Zhang D, Li H, Zhao Q, Gao H, Shi Z. Hijacking monopolar spindle 1 (MPS1) for various cancer types by small molecular inhibitors: Deep insights from a decade of research and patents. Eur J Med Chem 2024; 273:116504. [PMID: 38795520 DOI: 10.1016/j.ejmech.2024.116504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Revised: 05/03/2024] [Accepted: 05/13/2024] [Indexed: 05/28/2024]
Abstract
Monopolar spindle 1 (MPS1) has garnered significant attention due to its pivotal role in regulating the cell cycle. Anomalous expression and hyperactivation of MPS1 have been associated with the onset and advancement of diverse cancers, positioning it as a promising target for therapeutic interventions. This review focuses on MPS1 small molecule inhibitors from the past decade, exploring design strategies, structure-activity relationships (SAR), safety considerations, and clinical performance. Notably, we propose prospects for MPS1 degraders based on proteolysis targeting chimeras (PROTACs), as well as reversible covalent bonding as innovative MPS1 inhibitor design strategies. The objective is to provide valuable information for future development and novel perspectives on potential MPS1 inhibitors.
Collapse
Affiliation(s)
- Chengyuan Liang
- School of Biological and Pharmaceutical Sciences, Shaanxi University of Science & Technology, Xi'an, 710021, China; Key Laboratory for Antiviral and Antimicrobial-Resistant Bacteria Research of Xi'an, Xi'an, 710021, China.
| | - Ying Zhou
- School of Biological and Pharmaceutical Sciences, Shaanxi University of Science & Technology, Xi'an, 710021, China; Key Laboratory for Antiviral and Antimicrobial-Resistant Bacteria Research of Xi'an, Xi'an, 710021, China
| | - Liang Xin
- School of Biological and Pharmaceutical Sciences, Shaanxi University of Science & Technology, Xi'an, 710021, China; Key Laboratory for Antiviral and Antimicrobial-Resistant Bacteria Research of Xi'an, Xi'an, 710021, China
| | - Kairui Kang
- School of Biological and Pharmaceutical Sciences, Shaanxi University of Science & Technology, Xi'an, 710021, China; Key Laboratory for Antiviral and Antimicrobial-Resistant Bacteria Research of Xi'an, Xi'an, 710021, China
| | - Lei Tian
- Key Laboratory for Antiviral and Antimicrobial-Resistant Bacteria Research of Xi'an, Xi'an, 710021, China; College of Bioresources Chemical and Materials Engineering, Shaanxi University of Science& Technology, Xi'an, 710021, China
| | - Dezhu Zhang
- Key Laboratory for Antiviral and Antimicrobial-Resistant Bacteria Research of Xi'an, Xi'an, 710021, China; Shaanxi Panlong Pharmaceutical Group Co., Ltd., Xi'an, 710025, China
| | - Han Li
- School of Biological and Pharmaceutical Sciences, Shaanxi University of Science & Technology, Xi'an, 710021, China; Shaanxi Pioneer Biotech Co., Ltd., Xi'an, 710082, China
| | - Qianqian Zhao
- School of Biological and Pharmaceutical Sciences, Shaanxi University of Science & Technology, Xi'an, 710021, China; Key Laboratory for Antiviral and Antimicrobial-Resistant Bacteria Research of Xi'an, Xi'an, 710021, China
| | - Hong Gao
- Key Laboratory for Antiviral and Antimicrobial-Resistant Bacteria Research of Xi'an, Xi'an, 710021, China; Shaanxi Pioneer Biotech Co., Ltd., Xi'an, 710082, China
| | - Zhenfeng Shi
- Department of Urology Surgery Center, The People's Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, 830002, China
| |
Collapse
|
2
|
Zeng Y, Ren X, Jin P, Zhang Y, Zhuo M, Wang J. Development of MPS1 Inhibitors: Recent Advances and Perspectives. J Med Chem 2023; 66:16484-16514. [PMID: 38095579 DOI: 10.1021/acs.jmedchem.3c00963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2023]
Abstract
Monopolar spindle kinase 1 (MPS1) plays a pivotal role as a dual-specificity kinase governing spindle assembly checkpoint activation and sister chromatid separation in mitosis. Its overexpression has been observed in various human malignancies. MPS1 reduces spindle assembly checkpoint sensitivity, allowing tumor cells with a high degree of aneuploidy to complete mitosis and survive. Thus, MPS1 has emerged as a promising candidate for cancer therapy. Despite the identification of numerous MPS1 inhibitors, only five have advanced to clinical trials with none securing FDA approval for cancer treatment. In this perspective, we provide a concise overview of the structural and functional characteristics of MPS1 by highlighting its relevance to cancer. Additionally, we explore the structure-activity relationships, selectivity, and pharmacokinetics of MPS1 inhibitors featuring diverse scaffolds. Moreover, we review the reported work on enhancing MPS1 inhibitor selectivity, offering valuable insights into the discovery of novel, highly potent small-molecule MPS1 inhibitors.
Collapse
Affiliation(s)
- Yangjie Zeng
- Medical College, Guizhou University, Guiyang, Guizhou 550025, China
| | - Xiaodong Ren
- Medical College, Guizhou University, Guiyang, Guizhou 550025, China
| | - Pengyao Jin
- Medical College, Guizhou University, Guiyang, Guizhou 550025, China
| | - Yali Zhang
- Medical College, Guizhou University, Guiyang, Guizhou 550025, China
| | - Ming Zhuo
- Medical College, Guizhou University, Guiyang, Guizhou 550025, China
| | - Jubo Wang
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 210009, China
| |
Collapse
|
3
|
Abstract
Deregulation of cell cycle is a typical feature of cancer cells. Normal cells rely on the strictly coordinated spindle assembly checkpoint (SAC) to maintain the genome integrity and survive. However, cancer cells could bypass this checkpoint mechanism. In this study, we showed the clinical relevance of threonine tyrosine kinase (TTK) protein kinase, a central regulator of the SAC, in hepatocellular carcinoma (HCC) and its potential as therapeutic target. Here, we reported that a newly developed, orally active small molecule inhibitor targeting TTK (CFI-402257) effectively suppressed HCC growth and induced highly aneuploid HCC cells, DNA damage, and micronuclei formation. We identified that CFI-402257 also induced cytosolic DNA, senescence-like response, and activated DDX41-STING cytosolic DNA sensing pathway to produce senescence-associated secretory phenotypes (SASPs) in HCC cells. These SASPs subsequently led to recruitment of different subsets of immune cells (natural killer cells, CD4+ T cells, and CD8+ T cells) for tumor clearance. Our mass cytometry data illustrated the dynamic changes in the tumor-infiltrating immune populations after treatment with CFI-402257. Further, CFI-402257 improved survival in HCC-bearing mice treated with anti-PD-1, suggesting the possibility of combination treatment with immune checkpoint inhibitors in HCC patients. In summary, our study characterized CFI-402257 as a potential therapeutic for HCC, both used as a single agent and in combination therapy.
Collapse
|
4
|
Alizadeh SR, Ebrahimzadeh MA. Pyrazolotriazines: Biological activities, synthetic strategies and recent developments. Eur J Med Chem 2021; 223:113537. [PMID: 34147747 DOI: 10.1016/j.ejmech.2021.113537] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Revised: 05/03/2021] [Accepted: 05/10/2021] [Indexed: 10/21/2022]
Abstract
Heterocyclic compounds create an important class of molecules that demonstrates various chemical spaces for the definition of effective medicines. Many N-heterocycles display numerous biological activities. Among condensed heterocycles, pyrazolotriazine derivatives have received the attention of researchers owing to the extensive spectrum of biological activities. The reactivity of identified compounds was similar to the free azoles and triazines. The pyrazolotriazine scaffold exhibited antiasthma, antiinflammatory, anticancer, antithrombogenic activity and showed activity for major depression and pathological anxiety. Pyrazolotriazine derivatives also exhibited antibacterial, anticancer, antimetabolites, antidiabetic, antiamoebic, anticonvulsant, antiproliferative activity, human carbonic anhydrase inhibition, cyclin-dependent kinase 2 inhibition, tyrosinase and urease inhibition, MAO-B inhibition, TTK inhibition, thymidine phosphorylase inhibition, tubulin polymerization inhibition, protoporphyrinogen oxidase inhibition, GABAA agonistic activity, hCRF1 receptor antagonistic activity, and CGRP receptor antagonistic activity. This paper structurally categorized various pyrazolotriazines to isomeric classes into six groups that containing pyrazolo [1,5-d] [1,2,4] triazine, pyrazolo [5,1-c] [1,2,4] triazine, pyrazolo [3,4-e] [1,2,4] triazine, pyrazolo [4,3-e] [1,2,4] triazines, pyrazolo [1,5-a] [1,3,5] triazine, and pyrazolo [3,4-d] [1,2,3] triazine and expressed biological activity, the synthetic procedures for each class of pyrazolotriazines, structure-activity relationship and their mechanism of action. Generally, this review summarily indicated the past and present studies about the discovery of new lead compounds with good biological activity.
Collapse
Affiliation(s)
- Seyedeh Roya Alizadeh
- Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran
| | - Mohammad Ali Ebrahimzadeh
- Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.
| |
Collapse
|
5
|
Hebishy AMS, Salama HT, Elgemeie GH. New Route to the Synthesis of Benzamide-Based 5-Aminopyrazoles and Their Fused Heterocycles Showing Remarkable Antiavian Influenza Virus Activity. ACS OMEGA 2020; 5:25104-25112. [PMID: 33043189 PMCID: PMC7542596 DOI: 10.1021/acsomega.0c02675] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Accepted: 09/07/2020] [Indexed: 05/11/2023]
Abstract
This study describes a new route to the synthesis of novel benzamide-based 5-aminopyrazoles and their corresponding pyrazolo[1,5-a]pyrimidine and pyrazolo[5,1-c][1,2,4]triazine derivatives. Benzamide-based 5-aminopyrazoles were prepared through a reaction of benzoyl isothiocyanate with malononitrile in KOH-EtOH followed by alkylation with alkyl halides and then a reaction with hydrazine. In an attempt to react benzoyl isothiocyanate with ethyl cyanoacetate in KOH-EtOH followed by alkylation with methyl iodide at room temperature and then a reaction with hydrazine has resulted in the formation of 3-ethoxy-5-phenyl-1H-1,2,4-triazole. The structures of the new compounds were characterized by mass spectroscopy, 1H nuclear magnetic resonance (1H NMR) spectroscopy, infrared spectroscopy (IR), and X-ray analysis. The new compounds were tested in vitro for their anti-influenza A virus (subtype H5N1) activity. Among the synthesized compounds, eight compounds 3b, 4, 10b, 10c, 12a, 19, 21a, and 21b were found to possess significant antiviral activities against bird flu influenza (H5N1) with viral reduction in the range of 85-65%.
Collapse
|
6
|
Schulze VK, Klar U, Kosemund D, Wengner AM, Siemeister G, Stöckigt D, Neuhaus R, Lienau P, Bader B, Prechtl S, Holton SJ, Briem H, Marquardt T, Schirok H, Jautelat R, Bohlmann R, Nguyen D, Fernández-Montalván AE, Bömer U, Eberspaecher U, Brüning M, Döhr O, Raschke M, Kreft B, Mumberg D, Ziegelbauer K, Brands M, von Nussbaum F, Koppitz M. Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase. J Med Chem 2020; 63:8025-8042. [PMID: 32338514 DOI: 10.1021/acs.jmedchem.9b02035] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Inhibition of monopolar spindle 1 (MPS1) kinase represents a novel approach to cancer treatment: instead of arresting the cell cycle in tumor cells, cells are driven into mitosis irrespective of DNA damage and unattached/misattached chromosomes, resulting in aneuploidy and cell death. Starting points for our optimization efforts with the goal to identify MPS1 inhibitors were two HTS hits from the distinct chemical series "triazolopyridines" and "imidazopyrazines". The major initial issue of the triazolopyridine series was the moderate potency of the HTS hits. The imidazopyrazine series displayed more than 10-fold higher potencies; however, in the early project phase, this series suffered from poor metabolic stability. Here, we outline the evolution of the two hit series to clinical candidates BAY 1161909 and BAY 1217389 and reveal how both clinical candidates bind to the ATP site of MPS1 kinase, while addressing different pockets utilizing different binding interactions, along with their synthesis and preclinical characterization in selected in vivo efficacy models.
Collapse
Affiliation(s)
- Volker K Schulze
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Ulrich Klar
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Dirk Kosemund
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Antje M Wengner
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Gerhard Siemeister
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Detlef Stöckigt
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Roland Neuhaus
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Philip Lienau
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Benjamin Bader
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Stefan Prechtl
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Simon J Holton
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Hans Briem
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Tobias Marquardt
- Research & Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany
| | - Hartmut Schirok
- Research & Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany
| | - Rolf Jautelat
- Research & Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany
| | - Rolf Bohlmann
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Duy Nguyen
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | | | - Ulf Bömer
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Uwe Eberspaecher
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Michael Brüning
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Olaf Döhr
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Marian Raschke
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Bertolt Kreft
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Dominik Mumberg
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Karl Ziegelbauer
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Michael Brands
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Franz von Nussbaum
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Marcus Koppitz
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| |
Collapse
|
7
|
Anderhub SJ, Mak GWY, Gurden MD, Faisal A, Drosopoulos K, Walsh K, Woodward HL, Innocenti P, Westwood IM, Naud S, Hayes A, Theofani E, Filosto S, Saville H, Burke R, van Montfort RLM, Raynaud FI, Blagg J, Hoelder S, Eccles SA, Linardopoulos S. High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers. Mol Cancer Ther 2019; 18:1696-1707. [PMID: 31575759 DOI: 10.1158/1535-7163.mct-18-1203] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Revised: 03/21/2019] [Accepted: 07/01/2019] [Indexed: 11/16/2022]
Abstract
BOS172722 (CCT289346) is a highly potent, selective, and orally bioavailable inhibitor of spindle assembly checkpoint kinase MPS1. BOS172722 treatment alone induces significant sensitization to death, particularly in highly proliferative triple-negative breast cancer (TNBC) cell lines with compromised spindle assembly checkpoint activity. BOS172722 synergizes with paclitaxel to induce gross chromosomal segregation defects caused by MPS1 inhibitor-mediated abrogation of the mitotic delay induced by paclitaxel treatment. In in vivo pharmacodynamic experiments, BOS172722 potently inhibits the spindle assembly checkpoint induced by paclitaxel in human tumor xenograft models of TNBC, as measured by inhibition of the phosphorylation of histone H3 and the phosphorylation of the MPS1 substrate, KNL1. This mechanistic synergy results in significant in vivo efficacy, with robust tumor regressions observed for the combination of BOS172722 and paclitaxel versus either agent alone in long-term efficacy studies in multiple human tumor xenograft TNBC models, including a patient-derived xenograft and a systemic metastasis model. The current target indication for BOS172722 is TNBC, based on their high sensitivity to MPS1 inhibition, the well-defined clinical patient population with high unmet need, and the synergy observed with paclitaxel.
Collapse
Affiliation(s)
- Simon J Anderhub
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Grace Wing-Yan Mak
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Mark D Gurden
- The Breast Cancer Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom
| | - Amir Faisal
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Konstantinos Drosopoulos
- The Breast Cancer Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom
| | - Katie Walsh
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Hannah L Woodward
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Paolo Innocenti
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Isaac M Westwood
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Sébastien Naud
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Angela Hayes
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Efthymia Theofani
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Simone Filosto
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Harry Saville
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Rosemary Burke
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Rob L M van Montfort
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Florence I Raynaud
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Julian Blagg
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Swen Hoelder
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Suzanne A Eccles
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
| | - Spiros Linardopoulos
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
- The Breast Cancer Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom
| |
Collapse
|
8
|
Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective. Eur J Med Chem 2019; 175:247-268. [DOI: 10.1016/j.ejmech.2019.04.047] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2019] [Revised: 04/17/2019] [Accepted: 04/17/2019] [Indexed: 11/21/2022]
|
9
|
Riggs JR, Elsner J, Cashion D, Robinson D, Tehrani L, Nagy M, Fultz KE, Krishna Narla R, Peng X, Tran T, Kulkarni A, Bahmanyar S, Condroski K, Pagarigan B, Fenalti G, LeBrun L, Leftheris K, Zhu D, Boylan JF. Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy. J Med Chem 2019; 62:4401-4410. [PMID: 30998356 DOI: 10.1021/acs.jmedchem.8b01869] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Triple negative breast cancer (TNBC) is an aggressive disease with high relapse rates and few treatment options. Outlined in previous publications, we identified a series of potent, dual TTK/CLK2 inhibitors with strong efficacy in TNBC xenograft models. Pharmacokinetic properties and kinome selectivity were optimized, resulting in the identification of a new series of potent, selective, and orally bioavailable TTK inhibitors. We describe here the structure-activity relationship of the 2,4-disubstituted-7 H-pyrrolo[2,3- d]pyrimidine series, leading to significant single agent efficacy in a TNBC xenograft model without body weight loss. The design effort evolving an iv-dosed TTK/CLK2 inhibitor to an orally bioavailable TTK inhibitor is described.
Collapse
Affiliation(s)
- Jennifer R Riggs
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Jan Elsner
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Dan Cashion
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Dale Robinson
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Lida Tehrani
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Mark Nagy
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Kimberly E Fultz
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Rama Krishna Narla
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Xiaohui Peng
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Tam Tran
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Ashutosh Kulkarni
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Sogole Bahmanyar
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Kevin Condroski
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Barbra Pagarigan
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Gustavo Fenalti
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Laurie LeBrun
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Katerina Leftheris
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - Dan Zhu
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| | - John F Boylan
- Celgene Corporation , 10300 Campus Point Drive, Suite 100 , San Diego , California 92121 , United States
| |
Collapse
|
10
|
Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division. Br J Cancer 2018; 118:1586-1595. [PMID: 29736010 PMCID: PMC6008333 DOI: 10.1038/s41416-018-0081-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Revised: 03/12/2018] [Accepted: 03/20/2018] [Indexed: 11/21/2022] Open
Abstract
Background Chromosomal instability (CIN) is a common trait of cancer characterised by the continuous gain and loss of chromosomes during mitosis. Excessive levels of CIN can suppress tumour growth, providing a possible therapeutic strategy. The Mps1/TTK kinase has been one of the prime targets to explore this concept, and indeed Mps1 inhibitors synergise with the spindle poison docetaxel in inhibiting the growth of tumours in mice. Methods To investigate how the combination of docetaxel and a Mps1 inhibitor (Cpd-5) promote tumour cell death, we treated mice transplanted with BRCA1−/−;TP53−/− mammary tumours with docetaxel and/or Cpd-5. The tumours were analysed regarding their histopathology, chromosome segregation errors, copy number variations and cell death to understand the mechanism of action of the drug combination. Results The enhanced efficacy of combining an Mps1 inhibitor with clinically relevant doses of docetaxel is associated with an increase in multipolar anaphases, aberrant nuclear morphologies and cell death. Tumours treated with docetaxel and Cpd-5 displayed more genomic deviations, indicating that chromosome stability is affected mostly in the combinatorial treatment. Conclusions Our study shows that the synergy between taxanes and Mps1 inhibitors depends on increased errors in cell division, allowing further optimisation of this treatment regimen for cancer therapy.
Collapse
|
11
|
A new microwave-assisted, three-component reaction of 5-aminopyrazole-4-carboxylates: Selective synthesis of substituted 5-aza-9-deaza-adenines. Tetrahedron 2018. [DOI: 10.1016/j.tet.2018.02.054] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
12
|
|
13
|
Ahmadi F, Mirzaei P, Bazgir A. Cobalt-catalyzed isocyanide insertion cyclization to dihydrobenzoimidazotriazins. Tetrahedron Lett 2017. [DOI: 10.1016/j.tetlet.2017.09.088] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
14
|
Riggs JR, Nagy M, Elsner J, Erdman P, Cashion D, Robinson D, Harris R, Huang D, Tehrani L, Deyanat-Yazdi G, Narla RK, Peng X, Tran T, Barnes L, Miller T, Katz J, Tang Y, Chen M, Moghaddam MF, Bahmanyar S, Pagarigan B, Delker S, LeBrun L, Chamberlain PP, Calabrese A, Canan SS, Leftheris K, Zhu D, Boylan JF. The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen. J Med Chem 2017; 60:8989-9002. [PMID: 28991472 DOI: 10.1021/acs.jmedchem.7b01223] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Triple negative breast cancer (TNBC) remains a serious unmet medical need with discouragingly high relapse rates. We report here the synthesis and structure-activity relationship (SAR) of a novel series of 2,4,5-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines with potent activity against TNBC tumor cell lines. These compounds were discovered from a TNBC phenotypic screen and possess a unique dual inhibition profile targeting TTK (mitotic exit) and CLK2 (mRNA splicing). Design and optimization, driven with a TNBC tumor cell assay, identified potent and selective compounds with favorable in vitro and in vivo activity profiles and good iv PK properties. This cell-based driven SAR produced compounds with strong single agent in vivo efficacy in multiple TNBC xenograft models without significant body weight loss. These data supported the nomination of CC-671 into IND-enabling studies as a single agent TNBC therapy.
Collapse
Affiliation(s)
- Jennifer R Riggs
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Mark Nagy
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Jan Elsner
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Paul Erdman
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Dan Cashion
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Dale Robinson
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Roy Harris
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Dehua Huang
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Lida Tehrani
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Gordafaried Deyanat-Yazdi
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Rama Krishna Narla
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Xiaohui Peng
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Tam Tran
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Leo Barnes
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Terra Miller
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Jason Katz
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Yang Tang
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Ming Chen
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Mehran F Moghaddam
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Sogole Bahmanyar
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Barbra Pagarigan
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Silvia Delker
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Laurie LeBrun
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Philip P Chamberlain
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Andrew Calabrese
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Stacie S Canan
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Katerina Leftheris
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - Dan Zhu
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| | - John F Boylan
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States
| |
Collapse
|
15
|
Synthesis, antitumor evaluation and microarray study of some new pyrazolo[3,4-d][1,2,3]triazine derivatives. Eur J Med Chem 2017; 141:603-614. [PMID: 29107422 DOI: 10.1016/j.ejmech.2017.10.016] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Revised: 09/11/2017] [Accepted: 10/08/2017] [Indexed: 12/11/2022]
Abstract
Design and synthesis of new anticancer scaffolds; pyrazolo[3,4-d][1,2,3]triazine derivatives, is a promising solution to overcome drug resistance problem. A series of (E)-2-cyano-N-(aryl)-3-methylthio-3-(substituted-amino)acrylamides 3a-e was synthesized and transformed to the 3-aminopyrazole derivatives 4a-e which were then transformed to the target pyrazolotriazinones 6a-e. All compounds were evaluated for their anticancer activity against three different cancer cell lines namely Huh-7, Panc-1 and CCRF. Compounds 3a, 3c, 6a and 6c showed excellent anticancer activity against Huh-7 cell line (IC50: 4.93-8.84 μM vs doxorubicin 5.43 μM). Similarly, compounds 6a and 6d showed excellent activities against Panc-1 cells (IC50: 9.91 μM and 4.93 μM vs doxorubicin 6.90 μM). Caspase-Glo 3/7 assay was done and the results revealed that the pro-apoptotic activity of the target compounds could be due to the stimulation of caspases 3/7. Microarray experiment for Huh-7 cells treated with 6c was performed to search for other molecular changes. SLC26A3, UGT1A1, UGT2B15, UGT2B7, DNASE1, MUCDH1 and UGT2B17 were among the up-regulated genes, while, GIP3, TAGL, THBS1, IFI27, FSCN1 and SOCS2 were among the most extensively down-regulated genes. These genes belong to apoptosis, metabolism, cell cycle, tumor growth and suppressor genes. Finally, pyrazolo[3,4-d][1,2,3]triazine derivatives could be potent anticancer drugs in the future.
Collapse
|